Company profilePharmaceutical#431 of 1,318 in Pakistan✓ No DRAP alerts

QINTAR PHARMACUTICALS

Pharmaceutical company · 37 brands · 42 molecules

Ranked #202 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

37 registered products 18 pharmaceutical brands 42 distinct molecules 0 DRAP alerts

Company overview

37
registered products
18
pharmaceutical brands
42
distinct molecules
7
therapeutic classes
0
DRAP alerts

QINTAR PHARMACUTICALS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 37 product registrations across 42 distinct molecules. Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Antispasmodic & Anticholinergic. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 2Antispasmodic & Anticholinergic · 1Antiinflammatory And Antirheumatic Products · 1Antianemic, Iron Preparations · 1Quinolone Antibacterials · 1Other Beta-Lactam, Cephalosporins & Penems · 1Vitamin B12 Plain · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

FYNK PHARMACEUTICALS20 shared molecules
IRZA PHARMA (PVT) LTD.17 shared molecules
SHROOQ PHARMACEUTICALS16 shared molecules
BIO LABS (PVT) LTD.15 shared molecules
GLOBAL BRANDS DISTRIBUTORS15 shared molecules
VALOR PHARMACEUTICALS14 shared molecules

Get the full profile for QINTAR

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.